COMMUNIQUÉS West-GlobeNewswire

-
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
11/06/2025 -
Ocugen To Present at BIO International Convention 2025
11/06/2025 -
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
11/06/2025 -
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
11/06/2025 -
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
11/06/2025 -
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
11/06/2025 -
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
11/06/2025 -
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
11/06/2025 -
R1 Expands Finance and Corporate Development Teams with New Appointments
11/06/2025 -
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
11/06/2025 -
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
11/06/2025 -
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025 -
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
11/06/2025 -
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025 -
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
11/06/2025 -
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
11/06/2025 -
Elkedonia clôture un tour d’amorçage de 11 millions d’euros pour le développement de neuroplastogènes comme traitements novateurs contre la dépression et les troubles neuropsychiatriques
11/06/2025 -
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
11/06/2025 -
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
11/06/2025
Pages